Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Influence on quality of life of chemotherapy scheduling for patients with advanced HER2-negative breast cancer

Date

03 May 2019

Session

Poster lunch

Presenters

Anouk Claessens

Citation

Annals of Oncology (2019) 30 (suppl_3): iii47-iii64. 10.1093/annonc/mdz100

Authors

A.K.M. Claessens1, R. Timman2, J.J. Busschbach2, J.M. Bouma3, J.M. Rademaker-Lakhai4, F.L.G. Erdkamp1, V.C.G. Tjan-Heijnen5, M.M.E.M. Bos6

Author affiliations

  • 1 Internal Medicine - Oncology, Zuyderland Medical Center - Sittard-Geleen, 6162 BG - Sittard-Geleen/NL
  • 2 Psychiatry, Section Of Medical Psychology & Psychotherapy, Erasmus University Medical Center, 3015 GD - Rotterdam/NL
  • 3 Trial Registation, Comprehensive Cancer Centre the Netherlands, 3011 BN - Rotterdam/NL
  • 4 Boog Study Center, Dutch Breast Cancer Research Group, 1076 CV - Amsterdam/NL
  • 5 Medical Oncology, Maastricht University Medical Center (MUMC), 6202 AZ - Maastricht/NL
  • 6 Medical Oncology, Erasmus University Medical Center, 3015 CE - Rotterdam/NL
More

Resources

Abstract 290

Background

The phase III Stop&Go study randomized patients with advanced breast cancer to two times four intermittent cycles or to eight continuous cycles of first- and second-line chemotherapy, yielding inferior overall survival (OS) with intermittent scheduling. Here we report on the prospectively planned quality of life (QoL) analyses.

Methods

QoL was measured by RAND-36 questionnaires every 12 weeks during study treatment and follow-up. Physical and mental component scores were calculated and presented as T-scores with a mean of 50 and a standard deviation (SD) of 10 for the normal population, with higher scores representing better QoL. All patients who responded to baseline questionnaires with sufficient valid data were included. The primary objective was to describe the course of physical and mental QoL for both treatment arms, and to estimate differences in changes from baseline in physical and mental QoL between arms. These differences were estimated longitudinally with multilevel linear regression analyses with a follow up period of 30 months. An effect size of 0.5 SD (5 points) was considered clinically meaningful.

Results

A total of 398 patients were included with a median follow-up of 11.3 months (IQR 5.6 - 22.2). Mean baseline scores were 37.9 and 38.3 for physical, and 44.7 and 42.5 for mental QoL for intermittent and continuous treatment respectively. Physical QoL declined linearly in the intermittent arm causing a clinically meaningful difference of 5.68 points at 24 months (p < 0.001), while scores in the continuous arm stabilized after a decline of ± 3.5 points at 12 months. Conversely, mental QoL was fairly stable and even improved by 1.86 (p = 0.012) and 2.53 points (p = 0.001) at 12 months for intermittent and continuous treatment. When comparing the arms for both components in changes from baseline, the maximum differences were 3.11 points (p = 0.069) for physical and 3.32 points (p = 0.057) for mental scores, both measured at 30 months and in favor of continuous treatment.

Conclusions

Intermittent chemotherapy was less effective and showed a trend for worse impact on QoL compared to continuous chemotherapy in advanced breast cancer.

Editorial acknowledgement

Clinical trial identification

EudraCT 2010-021519-18; BOOG 2010-02.

Legal entity responsible for the study

Dutch Breast Cancer Research Group (BOOG).

Funding

F. Hoffmann-La Roche Ltd, The Netherlands TEVA Nederland, B.V.

Disclosure

F.L.G. Erdkamp: Honoraria, consulting/advisory role: Roche, Novartis. V.C.G. Tjan-Heijnen: Honoraria: E. Lilly, Pfizer; Funding for her institution: E. Lilly, Roche, Eisai, Pfizer, Novartis; Travel expenses: E. Lilly, Pfizer, Novartis, Roche; Consulting or advisory role: E. Lilly, Pfizer, Roche. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings